Saquinavir-soft gel: establishing saquinavir in HAART regimens

Bibliography

• BHIVA GUIDELINES CO-ORDINATING COMMITTEE: Brit-ish HIV Association guidelines for antiretroviral treat-ment of HIV seropositive individuals. Lancet (1997) 349:1086–1092.
   PubMed Web of Science ®Google Scholar
• CARPENTER CJ, FISCHL MA, HAMMER SM et al: Antiretro-viral therapy for HIV infection in 1998. JAMA (1998) 280:78–86.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Viral resistance patterns selected by antiret-roviral drugs and their potential to guide treatment choice. Exp. Opin. Invest. Drugs (1997) 6:943–964.
   PubMedGoogle Scholar
• HAUBRICH R, LALEZARI J, FOLLANSBEE SE et al.: Im-proved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther. (1998) 3:33–42.
   Web of Science ®Google Scholar
• VANHOVE GF, GRIES J-M, VEROTTA D et al.: Exposure-response relationship for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob. Agents Chemother. (1997) 41:2433–2438.
   PubMed Web of Science ®Google Scholar
• KOHL NE, EMINI EA, SCHLEIF WA et al: Active humanimmunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA (1988) 85:4686–4690.
   PubMed Web of Science ®Google Scholar
• ROBERTS NA, MARTIN JA, KINCHINGTON D et al.: Ra-tional design of peptide-based HIV proteinase inhibi-tors. Science (1990) 248:358–361.
   PubMed Web of Science ®Google Scholar
• MOYLE G: Saquinavir: a review of its development, pharmacological properties and clinical use. Exp. Opin. Invest. Drugs (1996) 5:155–167.
   Google Scholar
• MOYLE G, GAZZARD B: Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs (1996) 51:701–712.
   PubMed Web of Science ®Google Scholar
• GALPIN S, ROBERTS NA, O'CONNOR T et al: Antiviral properties of the 111V-1 protease inhibitor Ro 31-8959. Antiviral Chem. Chemother. (1994) 5:43–45.
   Web of Science ®Google Scholar
• SQV-SGC (saquinavir) soft gelatin capsules. US Pack-age Insert. Roche Laboratories, Inc. (November 1997).
   Google Scholar
• GIESCHKE R, BUSS N, STEIMER J-L: Exposure-response relationship between saquinavir pharmacokinetic characteristics and markers of efficacy (HIV RNA, CD4) in infected patients. 6t1 European Conference On Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany (Oct. 11–15, 1997). Abstract 454.
   Google Scholar
• BUSS N: Saquinavir soft gel capsule (SQV-SGC®): phar-macokinetics and drug interactions. 5t1 Conference on Retroviruses and Opportunistic Infections. Chicago, USA (Feb. 1–5, 1998). Abstract 354.
   Google Scholar
• MOYLE GJ, SADLER M, HAWKINS D, BUSS N: Correlation between plasma and CSF viral load in patients on saquinavir containing regimens. Pharmacokinetics (PK) of saquinavir at steady state in CSF and plasma. 6t1 European Conference on Clinical Aspects and treatment of HIV-Infection. Hamburg, Germany (Oct. 11–15, 1997).
   Google Scholar
• MOYLE GJ: The role of combinations of HIV protease inhibitors in management of persons with HIV infec-tion. Exp. Opin. Invest. Drugs (1998) 7:413–426.
   PubMedGoogle Scholar
• VON MOLTKE LL, GREENBLATT DJ, GRASSI JM et al.: Pro-tease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Phar-macol. (1998) 38:106–111.
   PubMed Web of Science ®Google Scholar
• SCHAPIRO JM, WINTERS MA, STEWART F et al.: Effects ofhigh dose saquinavir on viral load and CD4 T-cell counts in HIV infected patients. Ann. Intern. Med. (1996) 124:1039–1050.
   PubMed Web of Science ®Google Scholar
• MITSUYASU RT, SKOLNIK PR, COHEN SR et al. ON BE-HALF OF THE NV15355 STUDY GROUP: Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS (1998) 12:F103–F109.
   PubMed Web of Science ®Google Scholar
• SENSION M, FARTHING C, PALMER, PATTISON T et al.:SQV-SGC' (saquinavir soft gel capsule, SQV-SGC) in combination with AZT and 3TC in antiretroviral-naive 111V-1 infected patients. 5t1 National Conference on Retro-viruses and Opportunistic Infections. Chicago, USA (Feb. 1–5, 1998). Abstract 369.
   Google Scholar
• BOUCHER CAB, BORLEFFS JC, ON BEHALF OF THE CHEESE STUDY TEAM Long-term evaluation of saqui-navir soft gel capsules or indinavir as part of triple therapy regimen (CHEESE study). 12t World AIDS Conference. Geneva, Switzerland (June 28- July 3 1998). Ab-stract 12267.
   Google Scholar
• GILL MJ, BEALL G, BEATTIE D et al.: Safety of saquinavirsoft gelatin capsule (SQV-SGC) in combination with other retroviral agents: multicenter study NV15182: 24 week analysis. 31 Intel-science Conference on Antimicro-bial Agents and Chemotherapy. Toronto, Canada (Sept. 28 - Oct. 1, 1997). Abstract 1–90.
   Google Scholar
• MOYLE G, ON BEHALF OF THE SPICE STUDY TEAM: Study of protease inhibitor combination in Europe (SPICE) saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals. 12th World AIDS Conference. Geneva, Switzerland (June 28 - July 3, 1998). Abstract 12222.
   Google Scholar
• COHEN C, SIEMON-HRYCZK P, PILSON R et al.: Potent and convenient Fortovase (SQV) SGC BID regimens with 2 nucleosides or nelfinavir plus 1 nucleoside in 11IV-1 infected patients. 12th World AIDS Conference. Ge-neva, Switzerland (June 28 - July 3, 1998). Abstract 12314.
   Google Scholar
• NASCIMBENI M, PEYTAVIN G, FARINOTTI R, CLAVEL F: Kinetics of the antiviral activity of protease inhibitors in tissue culture. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lago Ma-giorre, Italy (June 24–27, 1998). Abstract 45.
   Google Scholar
• CALDWELL R, ROTHSTEIN A, ALLMON C, MONTOYA JG, ZOLOPA A: Evaluation of protease inhibitor associated hyperglycaemia in a University-based HIV clinic. 12th World AIDS Conference. Geneva, Switzerland (June 28 - July 3, 1998). Abstract 12395.
   Google Scholar
• HANG E, DELEO M, LIU YT, TETREAULT D, BEALL G: The effects of antiretroviral protease inhibitors (PIs) on serum lipids and glucose in HIV infected persons. 12th World AIDS Conference. Geneva, Switzerland (June 28- July 3, 1998). Abstract 12381.
   Google Scholar
• ROBERTS NA, CRAIG JC, SHELDON J: Resistance andcross-resistance with saquinavir and other HIV prote-ase inhibitors: theory and practice. AIDS (1998) 12:453–460.
   PubMed Web of Science ®Google Scholar
• ERMOLIEFF J, LIN X, TANG J: Kinetic properties of saqui-navir resistant mutants of 11IV-1 protease and their im-plications in drug resistance in vivo. Biochemistry (1997) 36:12364–12370.
   PubMed Web of Science ®Google Scholar
• CRAIG C, RACE E, SHELDON J et al.: Key amino acid sub-stitutions in HIV proteinase remain unaltered during increased exposure to saquinavir (SQV-SGC): results from preliminary trials. 6t1 European Conference On Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany (Oct. 11–15, 1997). Abstract 243.
   Google Scholar
• PARA MF, COOMBS R, COLLIER A et al.: Relationship of baseline genotype to RNA response in ACTG 333 after switching from long-term saquinavir (SQVhc) to indi-navir (IDV) or saquinavir soft gel capsule (SQVsgc). 5th National Conference on Retro viruses and Opportunistic In-fections. Chicago, USA (Feb 1–5, 1998). Abstract 511.
   Google Scholar
• MOYLE GJ, GAZZARD BG, COOPER DA, GATELL J: An-tiretroviral therapy for HIV infection: a knowledge-based approach to drug selection and use. Drugs (1998) 55:383–404.
   PubMed Web of Science ®Google Scholar